Edwards Lifesciences CorporationEWNYSE

|||

Overview News Chart Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating

Buy

21 analysts·High coverage

67%

Rating Distribution

Strong Buy

00%

Buy

1467%

Hold

733%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 13% higher.

Bear Case

$87.00

+3%

Base Case

$96.20

+13%

Bull Case

$105.00

+24%

Price Range21 analysts

Low

Consensus

High

$87.00

$105.00

Current Target

Current Price

$84.83

Upside to Target

$11.37

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$2.88(18 analysts)

P/E36x

Current: 36.4x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Recent Analyst Actions

Jan 7, 2026Stifel Nicolaus

Edwards Lifesciences price target raised to $105 from $100 at Stifel

Target:$105.00

+22.3%from $85.85

Jan 5, 2026Evercore ISI

Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI

Target:$94.00

+11.4%from $84.34

Dec 18, 2025Wells Fargo

JPMorgan Upgrades Edwards Lifesciences (EW) to Overweight

Target:$100.00

+17.9%from $84.84

Dec 17, 2025Canaccord Genuity

Edwards Lifesciences price target lowered to $87 from $89 at Canaccord

Target:$87.00

+2.0%from $85.32

Dec 16, 2025Robert W. Baird

Edwards Lifesciences price target lowered to $87 from $88 at Baird

Target:$87.00

+4.3%from $83.38

Dec 8, 2025Barclays

Edwards Lifesciences price target raised to $103 from $99 at Barclays

Target:$103.00

+19.5%from $86.19

Dec 5, 2025UBS

Edwards Lifesciences price target raised to $92 from $90 at UBS

Target:$92.00

+6.3%from $86.58

Dec 5, 2025RBC Capital

Edwards Lifesciences (EW) PT Raised at RBC Capital; 'A Catalyst Rich Year in 2026 and Beyond'

Target:$100.00

+14.5%from $87.33

Dec 5, 2025Robert W. Baird

Edwards Lifesciences price target raised to $88 from $83 at Baird

Target:$88.00

+2.6%from $85.78

Dec 5, 2025Canaccord Genuity

Edwards Lifesciences price target raised to $89 from $84 at Canaccord

Target:$89.00

+3.8%from $85.78

Dec 5, 2025Wells Fargo

Edwards Lifesciences price target raised to $96 from $95 at Wells Fargo

Target:$96.00

+11.9%from $85.78

Dec 5, 2025Stifel Nicolaus

Edwards Lifesciences (EW) PT Raised to $100 at Stifel

Target:$100.00

+16.6%from $85.78

Dec 5, 2025Truist Financial

Edwards Lifesciences (EW) PT Raised to $92 at Truist Securities

Target:$92.00

+7.3%from $85.78

Dec 4, 2025BTIG

Edwards Lifesciences price target raised to $103 from $100 at BTIG

Target:$103.00

+20.1%from $85.78

Nov 3, 2025Bernstein

Edwards Lifesciences (EW) PT Raised to $90 at Bernstein After a 'Strong Beat'

Target:$90.00

+9.2%from $82.45

Nov 3, 2025UBS

Edwards Lifesciences price target raised to $90 from $85 at UBS

Target:$90.00

+9.2%from $82.45

Nov 3, 2025Canaccord Genuity

Edwards Lifesciences (EW) PT Raised to $84 at Canaccord Genuity

Target:$84.00

+1.9%from $82.45

Nov 3, 2025Raymond James

Raymond James Upgrades Edwards Lifesciences (EW) to Outperform

Target:$96.00

+16.4%from $82.45

Oct 31, 2025National Bank

Edwards Lifesciences price target raised to $92 from $88 at Evercore ISI

Target:$92.00

+11.6%from $82.46

Oct 31, 2025Goldman Sachs

Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs

Target:$104.00

+23.1%from $84.48

Oct 31, 2025RBC Capital

Edwards Lifesciences price target raised to $95 from $89 at RBC Capital

Target:$95.00

+14.1%from $83.29

Oct 31, 2025Robert W. Baird

Edwards Lifesciences price target raised to $83 from $81 at Baird

Target:$83.00

-0.3%from $83.29

Oct 31, 2025Barclays

Edwards Lifesciences price target raised to $99 from $95 at Barclays

Target:$99.00

+18.6%from $83.48

Oct 29, 2025Jefferies

Jefferies Upgrades Edwards Lifesciences (EW) to Buy

Target:$98.00

+19.2%from $82.19

Oct 28, 2025Truist Financial

Edwards Lifesciences price target raised to $87 from $82 at Truist

Target:$87.00

+4.7%from $83.08

Oct 27, 2025Truist Financial

Truist says Edwards Lifesciences PARTNER 3 data driving unwind

Target:$82.00

+1.5%from $80.82

Oct 7, 2025Evercore ISI

Edwards Lifesciences upgraded to Outperform from In Line at Evercore ISI

Target:$88.00

+14.9%from $76.56

Sep 22, 2025Stifel Nicolaus

Edwards Lifesciences price target lowered to $85 from $95 at Stifel

Target:$85.00

+14.2%from $74.41

Apr 25, 2025Canaccord Genuity

Edwards Lifesciences price target raised to $75 from $71 at Canaccord

Target:$75.00

-1.4%from $76.04

Jan 29, 2025Stifel Nicolaus

Edwards Lifesciences upgraded to Buy from Hold at Stifel

Target:$90.00

+26.5%from $71.13

Jan 8, 2025Bernstein

Edwards Lifesciences price target raised to $74 from $72 at Bernstein

Target:$74.00

-0.2%from $74.15

Dec 5, 2024Bernstein

Bernstein SocGen Group Reiterates Market Perform Rating on Edwards Lifesciences (EW), 'Bullish Investor Day'

Target:$72.00

-0.9%from $72.63

Dec 5, 2024Truist Financial

Edwards Lifesciences (EW) PT Raised to $78 at Truist Securities

Target:$78.00

+7.4%from $72.64

Dec 5, 2024Canaccord Genuity

Edwards Lifesciences (EW) PT Raised to $68 at Canaccord Genuity

Target:$68.00

-7.2%from $73.25

Oct 30, 2024Goldman Sachs

Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

Target:$80.00

+16.6%from $68.63

Oct 30, 2024Bank of America Securities

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

Target:$75.00

+9.3%from $68.63

Oct 28, 2024Citigroup

Edwards Lifesciences TAVR data better than expected, says Citi

Target:$81.00

+17.3%from $69.05

Oct 15, 2024Robert W. Baird

Edwards Lifesciences (EW) PT Raised to $73 at Baird

Target:$73.00

+4.8%from $69.63

Oct 11, 2024Morgan Stanley

Edwards Lifesciences resumed with an Equal Weight at Morgan Stanley

Target:$70.00

+2.5%from $68.26

Oct 7, 2024Canaccord Genuity

Edwards Lifesciences price target lowered to $66 from $77 at Canaccord

Target:$66.00

+0.8%from $65.49

Sep 18, 2024Jefferies

Jefferies Downgrades Edwards Lifesciences (EW) to Hold

Target:$70.00

+4.1%from $67.23

Sep 13, 2024Truist Financial

Edwards Lifesciences (EW) PT Lowered to $71 at Truist Securities

Target:$71.00

+4.2%from $68.13

Sep 9, 2024Barclays

Edwards Lifesciences price target lowered to $80 from $90 at Barclays

Target:$80.00

+19.7%from $66.81

Sep 9, 2024Wells Fargo

Edwards Lifesciences price target lowered to $80 from $90 at Wells Fargo

Target:$80.00

+19.7%from $66.81

Jul 31, 2024Daiwa

Daiwa Securities Upgrades Edwards Lifesciences (EW) to Outperform (2)

Target:$72.00

+13.1%from $63.64

Jul 30, 2024Citigroup

Edwards Lifesciences (EW) PT Lowered to $83 at Citi

Target:$83.00

+30.2%from $63.74

Jul 25, 2024Oppenheimer

These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results

Target:$90.00

+48.6%from $60.58

Jul 25, 2024RBC Capital

These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results

Target:$85.00

+40.3%from $60.58

Jul 25, 2024J.P. Morgan

These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results

Target:$72.00

+18.9%from $60.58

Jul 25, 2024Deutsche Bank

These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results

Target:$85.00

+40.3%from $60.58

Jul 25, 2024Stifel Nicolaus

Edwards Lifesciences price target lowered to $70 from $85 at Stifel

Target:$70.00

-19.5%from $86.95

Jul 25, 2024Piper Sandler

Edwards Lifesciences price target lowered to $73 from $88 at Piper Sandler

Target:$73.00

-16.0%from $86.95

Jul 16, 2024Truist Financial

Edwards Lifesciences price target raised to $110 from $105 at Truist

Target:$110.00

+22.9%from $89.50

May 30, 2024Goldman Sachs

Goldman Sachs Starts Edwards Lifesciences (EW) at Buy

Target:$107.00

+22.9%from $87.03

May 14, 2024Deutsche Bank

Edwards Lifesciences (EW) PT Raised to $103 at Deutsche Bank, 'Evoque will bring EW back to its golden years'

Target:$103.00

+21.6%from $84.70

Apr 15, 2024RBC Capital

Edwards Lifesciences price target raised to $101 from $95 at RBC Capital

Target:$101.00

+11.9%from $90.28

Apr 11, 2024Mizuho Securities

Edwards Lifesciences price target raised to $105 from $95 at Mizuho

Target:$105.00

+14.7%from $91.51

Mar 18, 2024Oppenheimer

Edwards Lifesciences (EW) PT Raised to $100 at Oppenheimer

Target:$100.00

+7.7%from $92.85

Feb 1, 2023Canaccord Genuity

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $76

Target:$76.00

-2.8%from $78.21

Feb 1, 2023Truist Financial

Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $86

Target:$86.00

+12.1%from $76.70

Jan 6, 2023Morgan Stanley

Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95

Target:$95.00

+24.5%from $76.32

Dec 13, 2022Raymond James

Raymond James Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $83

Target:$83.00

+10.2%from $75.32

Dec 12, 2022Citigroup

Citigroup Maintains Buy on Edwards Lifesciences, Lowers Price Target to $92

Target:$92.00

+22.3%from $75.25

Dec 5, 2022Stifel Nicolaus

Edwards Lifesciences downgraded to Hold from Buy at Stifel

Target:$75.00

+1.6%from $73.85

Nov 28, 2022RBC Capital

RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $105

Target:$105.00

+38.2%from $75.98

Oct 28, 2022RBC Capital

Edwards Lifesciences (EW) PT Lowered to $118 at RBC Capital

Target:$118.00

+66.5%from $70.87

Jul 30, 2022Truist Financial

Edwards Lifesciences (EW) Stock: $120 Target And Buy Rating

Target:$120.00

+19.4%from $100.54

Apr 27, 2022Canaccord Genuity

Canaccord Genuity Maintains Buy on Edwards Lifesciences, Lowers Price Target to $137

Target:$137.00

+22.8%from $111.59

Apr 27, 2022Raymond James

Raymond James Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $124

Target:$124.00

+10.8%from $111.86

Apr 27, 2022RBC Capital

RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $135

Target:$135.00

+16.1%from $116.27

Apr 27, 2022Leerink Partners

SVB Leerink Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $138

Target:$138.00

+18.7%from $116.27

Apr 6, 2022Evercore ISI

Edwards Lifesciences (EW) Stock: $126 Price Target And Outperform Rating

Target:$126.00

+4.7%from $120.36

Mar 3, 2022Bank of America Securities

Edwards Lifesciences (EW) Stock: $130 Price Target And Neutral Rating

Target:$130.00

+16.1%from $111.98

Jan 27, 2022Stifel Nicolaus

Edwards Lifesciences (EW) PT Lowered to $120 at Stifel

Target:$120.00

+17.7%from $101.96

Jan 27, 2022Morgan Stanley

Edwards Lifesciences (EW) Received its Third Buy in a Row

Target:$136.00

+33.4%from $101.96

Jan 27, 2022Leerink Partners

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Anthem (NYSE: ANTM)

Target:$130.00

+27.5%from $101.96

Jan 26, 2022Deutsche Bank

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Sanofi (Other OTC: SNYNF)

Target:$113.00

+4.0%from $108.63

Jan 7, 2022Credit Suisse

Edwards Lifesciences price target raised to $144 from $131 at Credit Suisse

Target:$140.00

+14.5%from $122.30

Dec 17, 2021J.P. Morgan

Edwards Lifesciences upgraded to Overweight from Neutral at JPMorgan

Target:$140.00

+14.6%from $122.12

Dec 9, 2021Wells Fargo

Edwards Lifesciences price target raised to $133 from $126 at Wells Fargo

Target:$133.00

+10.5%from $120.34

Dec 9, 2021Oppenheimer

Edwards Lifesciences (EW) PT Raised to $135 at Oppenheimer

Target:$135.00

+12.2%from $120.34

Dec 9, 2021Cowen & Co.

Edwards Lifesciences (EW) PT Raised to $140 at Cowen; Named Best 2022 Idea

Target:$140.00

+16.3%from $120.34

Nov 8, 2021Jefferies

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), Edwards Lifesciences (NYSE: EW) and Perrigo Company (NYSE: PRGO)

Target:$135.00

+12.9%from $119.54

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance